Breast cancer shot could replace lengthy IV drips

NCT ID NCT04024462

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 3 trial tested whether a fixed-dose combination of two targeted drugs (pertuzumab and trastuzumab) given as a simple shot under the skin works as well as the standard IV infusion in 200 Chinese patients with HER2-positive early breast cancer. The study measured drug levels in the blood and checked how many patients had no cancer left after treatment. If the shot works, it could save patients time and make treatment more comfortable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pertuzumab and trastuzumab fixed-dose combination for subcutaneous injection (PH FDC SC)
What this could lead to: If successful, this could offer a more convenient, faster subcutaneous injection option instead of lengthy IV infusions for HER2-positive early breast cancer patients.
What could go wrong: This is a completed Phase 3 trial, but results may not apply to other populations or stages. The main focus is on drug levels in the blood, not long-term cure rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE EARLY BREAST CANCER

Contacts and locations

Locations

Beijing Cancer Hospital

Beijing, 100142, China
Fudan University Shanghai Cancer Center

Shanghai, 200032, China
Harbin Medical University Cancer Hospital

Harbin, 150081, China
Hebei Medical University Fourth Hospital

Shijiazhuang, 050035, China
Hubei Cancer Hospital

Wuhan, 430079, China
Jiangsu Province Hospital

Nanjing, 210036, China
Jilin Cancer Hospital

Changchun, 130012, China
Peking University People's Hospital

Beijing, 100044, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, 200025, China
Shandong Cancer Hospital

Jinan, 250117, China
Sun Yet-sen University Cancer Center

Guangzhou, 510060, China
The 900th Hospital of PLA joint service support force

Fuzhou, 110016, China
The Affiliated Hospital of Medical College Qingdao University

Qingdao, 266003, China
The First Affiliated Hospital of Xian Jiao Tong University

Xi'an, 710061, China
The First Hospital of Jilin University

Changchun, 130021, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, 430023, China
West China Hospital, Sichuan University

Chengdu, 610041, China
Zhejiang Cancer Hospital

Hangzhou, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.